These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38473433)

  • 1. The Combined Use of Inflammation Markers, Modified Glasgow Prognostic Score, and Sarculator Nomogram in Extremity Soft Tissue Sarcoma: A Multicenter Observational Study.
    Nakamura T; Takenaka S; Outani H; Hagi T; Tamiya H; Imura Y; Asanuma K; Sudo A
    Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
    Pasquali S; Palmerini E; Quagliuolo V; Martin-Broto J; Lopez-Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz-Beveridge R; Ferraresi V; Lugowska I; Infante G; Braglia L; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Bianchi G; Marrari A; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Miceli R; Casali PG; Gronchi A
    Cancer; 2022 Jan; 128(1):85-93. PubMed ID: 34643947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Stratification Tools to Aid Decisions on Adjuvant Chemotherapy Usage in Resected Soft Tissue Sarcomas: A Ten-Year Review of an Irish Sarcoma Center Experience.
    Weadick CS; Goggin C; Keogh RJ; Murphy JF; Feeley L; Bennett MW; O'Reilly S; Redmond HP; Kelly J; O'Mahony D; Noonan S; Clover AJP; Bambury RM
    World J Oncol; 2024 Aug; 15(4):640-647. PubMed ID: 38993253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial.
    Pasquali S; Colombo C; Pizzamiglio S; Verderio P; Callegaro D; Stacchiotti S; Martin Broto J; Lopez-Pousa A; Ferrari S; Poveda A; De Paoli A; Quagliuolo V; Jurado JC; Comandone A; Grignani G; De Sanctis R; Palassini E; Llomboart-Bosch A; Dei Tos AP; Casali PG; Picci P; Gronchi A
    Eur J Cancer; 2018 Apr; 93():28-36. PubMed ID: 29475197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
    Pasquali S; Pizzamiglio S; Touati N; Litiere S; Marreaud S; Kasper B; Gelderblom H; Stacchiotti S; Judson I; Dei Tos AP; Verderio P; Casali PG; Woll PJ; Gronchi A;
    Eur J Cancer; 2019 Mar; 109():51-60. PubMed ID: 30690293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified Glasgow Prognostic Score is Better for Predicting Oncological Outcome in Patients with Soft Tissue Sarcoma, Compared to High-Sensitivity Modified Glasgow Prognostic Score.
    Nakamura T; Asanuma K; Hagi T; Sudo A
    J Inflamm Res; 2022; 15():3891-3899. PubMed ID: 35845092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extremity Soft Tissue Sarcoma: A Multi-Institutional Validation of Prognostic Nomograms.
    Squires MH; Ethun CG; Donahue EE; Benbow JH; Anderson CJ; Jagosky MH; Manandhar M; Patt JC; Kneisl JS; Salo JC; Hill JS; Ahrens W; Prabhu RS; Livingston MB; Gower NL; Needham M; Trufan SJ; Fields RC; Krasnick BA; Bedi M; Votanopoulos K; Chouliaras K; Grignol V; Roggin KK; Tseng J; Poultsides G; Tran TB; Cardona K; Howard JH
    Ann Surg Oncol; 2022 May; 29(5):3291-3301. PubMed ID: 35015183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and Outcomes of Locally Recurrent Retroperitoneal Sarcoma After First Relapse in a Single Tertiary Asian Centre and Applicability of the
    Lim HJ; Wong R; Koh YS; Ho ZS; Ong CJ; Farid M; Teo CCM
    Front Oncol; 2021; 11():730292. PubMed ID: 34900680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic role of the preoperative systemic immune-inflammation index and high-sensitivity modified Glasgow prognostic score in patients after radical operation for soft tissue sarcoma.
    Hou T; Guo T; Nie R; Hong D; Zhou Z; Zhang X; Liang Y
    Eur J Surg Oncol; 2020 Aug; 46(8):1496-1502. PubMed ID: 32576479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic profiling improves prognostic risk stratification of the Sarculator nomogram in soft tissue sarcomas of the extremities and trunk wall.
    Chadha M; Iadecola S; Jenks A; Pankova V; Tam YB; Burns J; Arthur A; Wilding CP; Chen L; Chudasama P; Callegaro D; Strauss DC; Thway K; Gronchi A; Jones RL; Miceli R; Pasquali S; Huang PH
    Cancer Med; 2024 Jul; 13(14):e70026. PubMed ID: 39041188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the modified Glasgow Prognostic Score aid in the management of patients undergoing surgery for a soft-tissue sarcoma? : an international multicentre study.
    Spence S; Doonan J; Farhan-Alanie OM; Chan CD; Tong D; Cho HS; Sahu MA; Traub F; Gupta S;
    Bone Joint J; 2022 Jan; 104-B(1):168-176. PubMed ID: 34969280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study.
    Frezza AM; Stacchiotti S; Chibon F; Coindre JM; Italiano A; Romagnosa C; Bagué S; Dei Tos AP; Braglia L; Palmerini E; Quagliuolo V; Broto JM; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Beveridge RD; Lugowska I; Lesluyes T; Maestro R; Merlo FD; Casali PG; Gronchi A
    Cancer Med; 2023 Jan; 12(2):1350-1357. PubMed ID: 35848358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-institutional validation study of prognostic nomograms for retroperitoneal sarcoma.
    Squires MH; Ethun CG; Donahue EE; Benbow JH; Anderson CJ; Jagosky MH; Salo JC; Hill JS; Ahrens W; Prabhu RS; Livingston MB; Gower NL; Needham M; Trufan SJ; Fields RC; Krasnick BA; Bedi M; Abbott DE; Schwartz P; Votanopoulos K; Chouliaras K; Grignol V; Roggin KK; Tseng J; Poultsides G; Tran TB; Cardona K; Howard JH
    J Surg Oncol; 2021 Oct; 124(5):829-837. PubMed ID: 34254691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma.
    Higgins MI; Martini DJ; Patil DH; Nabavizadeh R; Steele S; Williams M; Joshi SS; Narayan VM; Sekhar A; Psutka SP; Ogan K; Bilen MA; Master VA
    Cancer; 2021 Jun; 127(12):1974-1983. PubMed ID: 33760232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
    Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
    Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer.
    Zhang Y; Chen S; Chen H; Li W
    Cancer Med; 2023 Jan; 12(1):38-48. PubMed ID: 35702873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial.
    Hacker UT; Hasenclever D; Baber R; Linder N; Busse H; Obermannova R; Zdrazilova-Dubska L; Valik D; Lordick F
    Ann Oncol; 2022 Jul; 33(7):685-692. PubMed ID: 35395383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glasgow prognostic score is a better predictor of the long-term survival in patients with gastric cancer, compared to the modified Glasgow prognostic score or high-sensitivity modified Glasgow prognostic score.
    Hirahara N; Matsubara T; Kaji S; Kawabata Y; Hyakudomi R; Yamamoto T; Uchida Y; Ishitobi K; Takai K; Tajima Y
    Oncotarget; 2020 Nov; 11(45):4169-4177. PubMed ID: 33227100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is a useful marker for predicting survival in patients with high-grade soft tissue sarcoma who have non-inflammatory conditions?
    Nakamura T; Asanuma K; Hagi T; Sudo A
    J Orthop Sci; 2024 Jul; 29(4):1125-1129. PubMed ID: 37537113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.
    Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
    Eur Arch Otorhinolaryngol; 2020 Aug; 277(8):2341-2347. PubMed ID: 32239313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.